Agile Therapeutics Q2 Adj $(3.10) Beats $(3.48) Estimate, Sales $5.50M Beat $4.68M Estimate
Portfolio Pulse from Benzinga Newsdesk
Agile Therapeutics (NASDAQ:AGRX) reported Q2 losses of $(3.10) per share, beating the analyst consensus estimate of $(7.00) by 55.71%. This is a 97.71% increase over losses from the same period last year. The company also reported quarterly sales of $5.50 million, beating the analyst consensus estimate of $4.08 million by 34.88%. This is a 158.84% increase over sales from the same period last year.
August 09, 2023 | 12:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Agile Therapeutics reported better than expected Q2 results with significant YoY improvements in losses per share and sales.
Agile Therapeutics reported better than expected Q2 results, beating estimates for both losses per share and sales. This indicates a strong financial performance, which is likely to positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100